Clinical Trial Update: Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65(III-healthy) [Phase 3]

View source ↗

Summary

Phase 3 trial of recombinant ESAT6-CFP10 allergen for tuberculosis in healthy adults completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Snippet

Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Conditions: Tuberculosis | Phase 3 | Status: COMPLETED